

Haeseong Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4038411/publications.pdf>

Version: 2024-02-01

81
papers

3,543
citations

279798

23
h-index

149698

56
g-index

82
all docs

82
docs citations

82
times ranked

4603
citing authors

#	ARTICLE	IF	CITATIONS
1	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 855-883.	4.9	672
2	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low Expressing Advanced Breast Cancer: Results From a Phase Ib Study. Journal of Clinical Oncology, 2020, 38, 1887-1896.	1.6	465
3	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer. JAMA Oncology, 2019, 5, 393.	7.1	303
4	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncology, The, 2019, 20, 816-826.	10.7	252
5	Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discovery, 2020, 10, 688-701.	9.4	212
6	Hydroxyurea for Sickle Cell Disease: A Systematic Review for Efficacy and Toxicity in Children. Pediatrics, 2008, 122, 1332-1342.	2.1	189
7	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncology, The, 2019, 20, 827-836.	10.7	154
8	A Systematic Review of Barriers and Interventions to Improve Appropriate Use of Therapies for Sickle Cell Disease. Journal of the National Medical Association, 2009, 101, 1022-1033.	0.8	135
9	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22a05): a single-arm, phase 1b/2 trial. Lancet Oncology, The, 2020, 21, 1066-1076.	10.7	130
10	Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 279-291.	10.7	118
11	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
12	Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.. Journal of Clinical Oncology, 2018, 36, 2501-2501.	1.6	68
13	Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. Cancer Immunology Research, 2020, 8, 451-464.	3.4	63
14	Acute Changes in N-Terminal Pro-B-Type Natriuretic Peptide During Hospitalization and Risk of Readmission and Mortality in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 1191-1195.	1.6	61
15	Usefulness of Cystatin C and Prognosis Following Admission for Acute Heart Failure. American Journal of Cardiology, 2009, 104, 389-392.	1.6	46
16	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, 7, 67521-67531.	1.8	44
17	Tolerability and safety of EUS-injected adenovirus-mediated double-suicide gene therapy with chemotherapy in locally advanced pancreatic cancer: a phase 1 trial. Gastrointestinal Endoscopy, 2020, 92, 1044-1052.e1.	1.0	43
18	Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. Oncologist, 2019, 24, 219-228.	3.7	30

#	ARTICLE	IF	CITATIONS
19	A pilot phase II trial of magnesium supplements to reduce menopausal hot flashes in breast cancer patients. <i>Supportive Care in Cancer</i> , 2011, 19, 859-863.	2.2	27
20	KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS146-TPS146.	1.6	27
21	ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine. <i>JCO Precision Oncology</i> , 2021, 5, 378-388.	3.0	26
22	First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2508-2508.	1.6	26
23	First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response. <i>Clinical Cancer Research</i> , 2022, 28, 3695-3708.	7.0	26
24	Targeting <i>HER2</i> (<i>ERBB2</i>) mutation-positive advanced biliary tract cancers with neratinib: Results from the phase II SUMMIT “basket” trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 320-320.	1.6	24
25	Race and ethnicity representation in clinical trials: findings from a literature review of Phase I oncology trials. <i>Future Oncology</i> , 2021, 17, 3271-3280.	2.4	24
26	Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 108-108.	1.6	23
27	Nonoperative Rectal Cancer Management With Short-Course Radiation Followed by Chemotherapy: A Nonrandomized Control Trial. <i>Clinical Colorectal Cancer</i> , 2021, 20, e185-e193.	2.3	20
28	North Central Cancer Treatment Group N10C2 (Alliance). <i>Menopause</i> , 2015, 22, 627-632.	2.0	18
29	Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL+ leukemia cells. <i>Leukemia Research</i> , 2015, 39, 65-71.	0.8	18
30	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020, 26, 5579-5587.	7.0	16
31	Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 985-989.	1.4	14
32	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. <i>JAMA Oncology</i> , 2020, 6, 1231.	7.1	12
33	Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 427-435.	2.5	11
34	Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. <i>Translational Research</i> , 2021, 231, 124-138.	5.0	11
35	First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2701-TPS2701.	1.6	10
36	A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. <i>Journal of Thoracic Disease</i> , 2021, 13, 4054-4062.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Margetuximab (M) plus pembrolizumab (P) in ERBB2-amplified PD-L1+ gastroesophageal adenocarcinoma (GEA) post trastuzumab (T).. Journal of Clinical Oncology, 2018, 36, 4030-4030.	1.6	9
38	Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, <i>HER2</i>-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	1.6	9
39	Phase Ia dose-escalation study of the anti-BTLA antibody icatolimab as a monotherapy in patients with advanced solid tumor.. Journal of Clinical Oncology, 2022, 40, 2643-2643.	1.6	9
40	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1102-TPS1102.	1.6	7
41	A randomized phase II study of nab-paclitaxel + durvalumab + neoantigen vaccine versus nab-paclitaxel + durvalumab in metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2019, 37, TPS1114-TPS1114.	1.6	6
42	Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, <i>HER2</i>-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. Cancer Research, 2022, 82, GS4-10-GS4-10.	0.9	6
43	Disseminated histoplasmosis in peripheral blood smear. Blood, 2014, 123, 1445-1445.	1.4	5
44	A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 2021, 87, 337-347.	2.3	5
45	Updated results of phase 1 study of DS-8201a in subjects with HER2-expressing gastric cancer.. Journal of Clinical Oncology, 2018, 36, 118-118.	1.6	5
46	A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.. Journal of Clinical Oncology, 2018, 36, TPS3127-TPS3127.	1.6	4
47	Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.. Journal of Clinical Oncology, 2019, 37, 4032-4032.	1.6	4
48	A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS375-TPS375.	1.6	4
49	Phase 1b/2, open-label, dose-escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in progress).. Journal of Clinical Oncology, 2022, 40, TPS376-TPS376.	1.6	4
50	Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.. Journal of Clinical Oncology, 2022, 40, 518-518.	1.6	4
51	Progress in PD-1-based Immunotherapy: New Mechanistic Insight May Provide Expanded Hope for Application to Colon and Gastrointestinal Cancers. Gastroenterology, 2017, 153, 1162-1163.	1.3	3
52	Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. Cancers, 2020, 12, 592.	3.7	3
53	Phase I study of BJ-001, a tumor-targeting interleukin-15 fusion protein, in patients with solid tumor.. Journal of Clinical Oncology, 2021, 39, e14545-e14545.	1.6	3
54	Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.. Journal of Clinical Oncology, 2021, 39, TPS3161-TPS3161.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 3031-3031.	1.6	2
56	A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2018, 36, 89-89.	1.6	2
57	A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET.. Journal of Clinical Oncology, 2020, 38, TPS3663-TPS3663.	1.6	2
58	SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.. Journal of Clinical Oncology, 2022, 40, TPS363-TPS363.	1.6	2
59	A pilot study of liposomal irinotecan plus 5-FU/ LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy.. Journal of Clinical Oncology, 2022, 40, 566-566.	1.6	2
60	First-in-human study of the B7-H4 antibody-drug conjugate (ADC) AZD8205 in patients with advanced/metastatic solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS3153-TPS3153.	1.6	2
61	A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinoma. Clinical and Translational Radiation Oncology, 2021, 30, 19-25.	1.7	1
62	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, TPS4150-TPS4150.	1.6	1
63	Abstract CT212: Combining pembrolizumab with locally delivered radiation therapy for the treatment of metastatic esophageal cancer. , 2019, , .		1
64	Initial safety run-in findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer.. Journal of Clinical Oncology, 2020, 38, e16537-e16537.	1.6	1
65	Reply to T.J.A. Dekker. Journal of Clinical Oncology, 2020, 38, 3351-3352.	1.6	0
66	A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.. Journal of Clinical Oncology, 2021, 39, TPS4157-TPS4157.	1.6	0
67	Capitalizing on Success of Systemic Therapy to Improve Outcomes of Intermediate-Stage HCC. JCO Oncology Practice, 2021, , OP.21.00451.	2.9	0
68	Selection of Neoadjuvant Treatment Arms in Trials of Patients With Squamous Cell Cancer of the Esophagus. JAMA Surgery, 2022, 157, 83.	4.3	0
69	NCCTG N10C2 (Alliance): A double-blind, placebo-controlled study of magnesium supplements to reduce menopausal hot flashes.. Journal of Clinical Oncology, 2014, 32, 9508-9508.	1.6	0
70	Abstract CT405: A phase 1 study of neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel, followed by concurrent chemoradiation with gemcitabine, sorafenib, and vorinostat in locally advanced pancreatic cancer. , 2014, , .		0
71	Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. Journal of Clinical Oncology, 2015, 33, 2584-2584.	1.6	0
72	Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.. Journal of Clinical Oncology, 2018, 36, 3578-3578.	1.6	0

#	ARTICLE	IF	CITATIONS
73	A phase Ib trial of anti-VEGFR/PDGFR vorolanib combined with immune checkpoint inhibitors (CPIs) in solid tumors.. Journal of Clinical Oncology, 2019, 37, TPS472-TPS472.	1.6	0
74	A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.. Journal of Clinical Oncology, 2019, 37, TPS41-TPS41.	1.6	0
75	Final results of a phase II trial of first-line FOLFIRINOX for advanced gastroesophageal cancers.. Journal of Clinical Oncology, 2020, 38, 4532-4532.	1.6	0
76	A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.. Journal of Clinical Oncology, 2020, 38, TPS793-TPS793.	1.6	0
77	Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.. Journal of Clinical Oncology, 2022, 40, 284-284.	1.6	0
78	Abstract OT1-02-02: A global, phase 2 study of ARX788 in patients with HER2-positive metastatic breast cancer whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. Cancer Research, 2022, 82, OT1-02-02-OT1-02-02.	0.9	0
79	Abstract 4182: Community and cancer registry collaboration to reduce persistent stomach cancer disparity in Korean Americans: Asian American Stomach Cancer Task Force. , 2019, , .		0
80	Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens.. Journal of Clinical Oncology, 2022, 40, TPS1112-TPS1112.	1.6	0
81	Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.. Journal of Clinical Oncology, 2022, 40, TPS4168-TPS4168.	1.6	0